by TractManager | Jun 12, 2019 | Emerging Technology Report
Polivy (polituzumab-vedotin-piiq) is an intravenously administered CD79b-directed antibody-drug conjugate indicated in combination with a rituximab product and bendamustine for adult patients with relapsed/refractory diffuse large B-cell lymphoma after at least 2...
by TractManager | Jun 12, 2019 | Emerging Technology Report
Polivy (polituzumab-vedotin-piiq) is an intravenously administered CD79b-directed antibody-drug conjugate indicated in combination with a rituximab product and bendamustine for adult patients with relapsed/refractory diffuse large B-cell lymphoma after at least 2...
by TractManager | Jun 11, 2019 | Health Technology Assessment
Health Problem: Hepatocellular carcinoma (HCC) is the most common liver malignancy in the United States, accounting for approximately 90% of primary liver cancers. The definitive therapies for HCC are surgical resection, tumor ablation, and liver transplantation;...
Recent Comments